Summary: Health Canada’s new Canadian Clinical Trial Search Portal makes it easier to find clinical trials authorized in Canada by condition, treatment, location, recruitment status and more. For people living with rare metabolic disorders and their families, it provides a simpler way to discover research opportunities taking place closer to home.

Summary: Pegtibatinase is an investigational enzyme replacement therapy being studied for classical homocystinuria caused by cystathionine beta synthase deficiency. The clinical development program includes the COMPOSE, HARMONY and ENSEMBLE studies, with HARMONY currently evaluating the therapy in a pivotal Phase 3 trial.

Summary: Research following adults with MSUD found that executive and adaptive functioning can affect education, employment, health-care transition and independent living, even among people receiving modern metabolic care. Newer findings also highlight the wide range of adult experiences and the need for more intentional support as people with MSUD transition from pediatric care into adult life.

Summary: A small study in children with MSUD explored whether ready-to-use liquid valine and isoleucine could provide a more practical alternative to traditional amino acid supplements. Published in 2026, the findings suggest the liquid products were well tolerated and may help simplify supplementation, although the study was small and the results should be considered exploratory.

Summary: A long-running international study of people with urea cycle disorders has helped researchers understand how UCDs affect health, development, cognition, quality of life and long-term outcomes. Nearly two decades of data from the Urea Cycle Disorders Consortium continue to inform research, clinical care and the design of future studies.

Summary: Repinatrabit, also known as JNT-517, is an investigational oral treatment being studied for PKU through a global Phase 3 program. As of September 2026, the Phase 3 study is recruiting adults with PKU, including at the M.A.G.I.C. Clinic in Calgary.

Summary: The PALomino study is collecting real-world information about pregnancy, breastfeeding and infant outcomes following exposure to Palynziq (pegvaliase) in people with PKU. Earlier case reports and small retrospective studies have provided encouraging information, but the evidence remains limited, making ongoing systematic pregnancy research especially important.

Summary: The APHENITY clinical program helped establish the evidence for sepiapterin, an oral treatment for PKU now approved in Canada as Sephience. Phase 3 and long-term extension research showed meaningful reductions in blood phenylalanine and, for many participants, increased dietary phenylalanine tolerance.

Summary: RareKids-CAN is inviting youth with rare diseases and caregivers to share how they search for and use medication-related information. The study aims to identify gaps in current resources and help shape clearer, more useful pharmacology education for rare-disease families across Canada.

Summary: Aurora Therapeutics Deprioritizes Its PKU Gene-Editing Program